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Abstract: Analysis of the temporal, seasonal and demographic distribution of dengue virus (DENV)
infections in Barbados was conducted using national surveillance data from a total of 3994 confirmed
dengue cases. Diagnosis was confirmed either by DENV–specific real time reverse transcriptase
polymerase chain reaction (rRT–PCR), or non–structural protein 1 (NS1) antigen or enzyme linked
immunosorbent assay (ELISA) tests; a case fatality rate of 0.4% (10/3994) was observed. The prevalence
rate of dengue fever (DF) varied from 27.5 to 453.9 cases per 100,000 population among febrile patients
who sought medical attention annually. DF cases occurred throughout the year with low level of
transmission observed during the dry season (December to June), then increased transmission during
rainy season (July to November) peaking in October. Three major dengue epidemics occurred in
Barbados during 2010, 2013 and possibly 2016 with an emerging three–year interval. DF prevalence
rate among febrile patients who sought medical attention overall was highest among the 10–19
years old age group. The highest DF hospitalisation prevalence rate was observed in 2013. Multiple
serotypes circulated during the study period and Dengue virus serotype 2 (DENV–2) was the most
prevalent serotype during 2010, whilst DENV–1 was the most prevalent serotype in 2013. Two DENV–1
strains from the 2013 DENV epidemic were genetically more closely related to South East Asian strains,
than Caribbean or South American strains, and represent the first ever sequencing of DENV strains in
Barbados. However, the small sample size (n = 2) limits any meaningful conclusions. DF prevalence
rates were not significantly different between females and males. Public health planning should
consider DENV inter–epidemic periodicity, the current COVID–19 pandemic and similar clinical
symptomology between DF and COVID–19. The implementation of routine sequencing of DENV
strains to obtain critical data can aid in battling DENV epidemics in Barbados.
Keywords: dengue; severe dengue; genetic sequencing; DENV; epidemiology; arbovirus; public
health; epidemics; Barbados; Caribbean
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1. Introduction
Dengue fever (DF) is the most prevalent human arboviral disease in tropical and subtropical
regions worldwide. Dengue virus (DENV) is a global health threat that is primarily acquired through
the bites of infected mosquitoes and responsible for over 100 million infections and 20,000 deaths
annually [1,2].
Current dengue epidemiology research aids in vaccine planning initiatives as it describes the
transmission dynamics within a population and the possible risk factors for DENV infections. In the
Latin America and Caribbean, such epidemiological data is varied in approach which can lead to
inconsistencies on the impact of age on disease burden and severity [3]. Dengue has been endemic in
Barbados for over 30 years with the circulation of all four DENV serotypes [4–12]. Barbados has two
annual seasons namely a dry and wet season. The dry season occurs from December–May and the
wet/rainy season from June to November. DENV infection is transmitted year–round in Barbados and
dengue epidemics have occurred in 1995, 1997, 2001, and 2007 [6,7,9]. Notably, dengue haemorrhagic
fever (DHF) in Barbados and the Caribbean does not appear to be as prevalent as in other Asian
countries where dengue is more severe. Current systematic population data on dengue epidemiology
in Barbados within the last 10 years has been absent. A recent dengue epidemiology study involved
children up to 16 years old (2000–2009) but lacked detailed data on the entire population [8].
We present epidemiological data across Barbados from a centralised laboratory where all suspected
and confirmed dengue cases in the island are tested. We also performed virus sequencing on the
envelope (E) gene of two DENV strains that were obtained from two real–time reverse transcriptase
polymerase chain reaction– (rRT–PCR) positive out of 33 patient sera.
2. Materials and Methods
2.1. Ethical Approval
The study (IRB No. 181110–A) was approved by Institutional Review Board (IRB) on Ethics in
Research on Human Subjects at The University of the West Indies (UWI), Cave Hill, St. Michael,
Barbados combined with the Ministry of Health on 11 July 2013 and the Ethics Committee at the Queen
Elizabeth Hospital (QEH), Martindale’s Road, St. Michael, Barbados on 19 August 2013 prior to the
start of data collection and analyses.
2.2. Sample Collection
All suspected febrile patients who seek medical attention on the island are referred to the central
public health laboratory based on the similarity of clinical symptoms of DENV, chikungunya virus
(CHIKV), Zika virus (ZIKV), Leptospira and hantavirus infections including fever, malaise, myalgia,
arthralgia, rash, retro–orbital pain, abdominal pain, nausea and vomiting. Random sampling of
patients from this database then permits a good representation of the entire population in Barbados
with febrile illness who sought medical attention. Dengue is a reportable disease in Barbados using a
functional passive surveillance system. The amalgamated Barbados public health laboratory is the
sole laboratory where all suspected dengue/leptospirosis febrile patients are tested for confirmation of
DENV, hantavirus, CHIKV, ZIKV and Leptospira infections.
All dengue cases, including probable and confirmed cases were diagnosed per the case definitions
issued by Barbados Ministry of Health. A DF and DHF case were defined as per the 1997 WHO
dengue guidelines for 2008 and a DF and severe dengue (SD) case were defined as per the 2009 WHO
dengue guidelines for 2009–2016. Dengue cases were registered using surveillance forms issued by
the Barbados Ministry of Health. These data were from suspected febrile patients tested for several
infections including DENV, Leptospira, CHIKV, ZIKV and hantavirus. A dengue epidemic was defined
by a significant difference in DENV prevalence rates between the preceding year and the epidemic
year where the DENV prevalence rate is significantly higher in the epidemic year compared to the
preceding year.
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Using a centralised patient database at the laboratory, a list of 3994 laboratory confirmed dengue
cases were identified by DENV–specific rRT–PCR, immunoglobulin M (IgM) and immunoglobulin G
(IgG) enzyme linked immunosorbent assay (ELISA) and non-specific protein 1 (NS1) antigen testing
in Barbados during 2008 to 2016. This list of patients was analysed and pertinent epidemiological
characteristics of infection including age, new dengue case, gender and geographical location during
this period were reported. The list of patients was exported from Microsoft Access as a Microsoft
Excel file for analysis. The patients were first grouped by year of dengue infection for the period of
study 2008–2016 (Figure 1). Using Microsoft Excel, each of the groups were sorted by age and the
list of total patients was reduced to 3894 out of the original 3994 patients (97.5%) as some of patients’
ages were not recorded. Each year group was sorted by age and the tally of each age group recorded.
Age standardisation was done using World Health Organization (WHO) standard [13].
Figure 1. Sampling and analysis of dengue fever (DF) patients, Barbados, 2008–2016.
For analysis by gender, all 3994 laboratory confirmed dengue patients were used (100%) as all
patients had their gender recorded. Each group was sorted by gender and the tally of patients for each
gender was recorded. For analysis by geographic location, only 80.4% (3340/3994) were used as a parish
address was missing for 19.6% of dengue cases on the list generated. From these, 3340 dengue patients
each group was sorted by parish and the tally of patients for each parish was recorded. For analysis of
new dengue cases, 3095 laboratory confirmed dengue patients were used (77.5%) with both IgM and
IgG results. These new cases were sorted by age and gender and the tallies of patients were recorded.
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2.3. Dengue Diagnosis
Laboratory confirmation of dengue cases were conducted via either detection of DENV–specific
IgM and IgG in patients’ serum with dengue IgM and IgG antibody–capture ELISA kits (samples
within 5–15 days of illness), or NS1 antigen or rRT–PCR (samples within the first five days of illness).
IgG and IgM antibody–capture ELISAs were performed per manufacturer’s instructions (Focus
Diagnostics, Cypress, CA90630 USA) [14,15]. Platelia™ Dengue NS1 Ag–ELISA (Biorad Laboratories,
Marnes–La–Coquette, France) was used for the NS1 antigen detection [16]. The patient sera were tested
using rRT–PCR to serotype the infecting DENV strain(s) as per the public health laboratory’s dengue
RT–PCR serotyping procedure [17]. For each testing assay, the relevant kit and in–house positive and
negative controls were used for quality control. A primary/new dengue case was defined by either the
presence of DENV–specific viral RNA (vRNA), NS1 antigen or DENV–specific IgM along with the
absence of DENV–specific IgG.
2.4. Virus Sequencing—Next Generation Sequencing (NGS)
Primers were designed for the E gene that allowed five fragments of sizes between up to 500
nucleotides, with about 50 nucleotides of overlap to be generated. Real time reverse transcriptase
polymerase chain reaction (rRT-PCR) was conducted using random primers (Invitrogen) and Superscript
III (Invitrogen), and deoxyribonucleotide (DNA) amplification was performed using the specific primers
and PFU polymerase (Invitrogen). Fragments were gel–purified using QIAquick gel extraction kit
(Qiagen, Venlo, The Netherlands) and were organized in libraries of equal concentrations. Libraries
were created for each virus without DNA fragmentation (GS FLX Titanium Rapid Library Preparation,
Roche), emPCR (Amplification Method Lib–L) and GS junior sequencing runs were performed
according to instructions of the manufacturer (Roche). Amplicons were sequenced in a blinded fashion
using 454 technology. Reads from the GS–FLX sequencing data were sorted by bar code and aligned to
reference sequences using CLC Genomics software 4.6.1. Using the alignment, a single nucleotide
polymorphism (SNP) table was made with a minimum coverage of 10 reads and a minimum variant
frequency of 1.0%. Raw nucleotide sequences were filtered, aligned, trimmed and translated using
pre–specified criteria applied uniformly so that all the protein E sequences used in the analyses spanned
the exo–domain and the transmembrane region.
2.5. Phylogenetic Analysis
The phylogenetic analysis was performed using MEGA version 6, considering sequences dengue
virus envelope (DENV–E) gene obtained in the present study (viz. DS18 and DS29) with global
reference sequences of different dengue serotype (DENV–1, –2, –3 and –4) and DENV–1 sequences
from different geographic regions, available in the GenBank database. The nucleotide sequences were
aligned using MUSCLE v.3.6. and the phylogenetic tree was generated considering complete envelop
gene (E) of DENV, using the maximal likelihood method (ML) based on Tamura–Nei (TN93) + gamma
model. Reliability of the analysis was evaluated by a bootstrap test with 1000 replications.
2.6. Data Analysis
Data analysis was done using Microsoft Excel (Microsoft, Redmond, WA, USA) and SPSS 16.0
software (SPSS Inc., Chicago, IL, USA) for statistical analysis. Confidence intervals (95%) were
calculated for all rates. Prevalence, case fatality risk/rate (CFR) and hospitalisation rates were calculated
using Barbados 2010 census data and Barbados population data from 2014. CFR is the number
of persons who died ÷ number of persons infected. A probability (p) of ≤ 0.05 was considered
statistically significant.
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3. Results
3.1. Laboratory Testing and Clinical Symptoms
The largest number of diagnostic tests were performed in 2013 (Table 1). The most common
clinical symptoms observed among DENV–infected patients in Barbados were fever, headache, joint
pain, retro–orbital pain, muscle pain and gastrointestinal symptoms (Table 2). More severe symptoms
such as bleeding, jaundice, thrombocytopenia and hepatomegaly (usually <12%) were not observed in
a high proportion of DENV cases (Table 2).
Table 1. Epidemiological and laboratory testing features of dengue virus (DENV) infections in
Barbados, 2008–2016.
Year No. of
Cases
Males Females
DENV
Serotypes
No. of
SD/DHF
Cases
No. of
Deaths
Diagnostic Testing
ELISA
IgM NS1 rRT–PCR
2008 147 70 77 n/a 0 0 147 – –
2009 76 35 40 3 3 0 76 – –
2010 542 265 275 1,2 *,3,4 33 3 491 55 5
2011 217 103 114 1,2 *,4 9 5 206 16 11
2012 464 218 245 1 *,2,4 13 2 428 85 78
2013 1260 594 665 1 *,2,4 5 0 947 375 143
2014 523 248 274 n/a 0 0 521 14 –
2015 123 72 52 n/a 0 0 124 4 –
2016 642 406 227 n/a 0 0 642 3 23
TOTAL 3994 2011 1969 63 10 3582 548 237
*—Predominant DENV subtype; n/a—not available. Note: All patients with DENV–specific enzyme linked
immunosorbent assay (ELISA) immunoglobulin G (IgG) negative ELISA results in combination with either
DENV–positive ELISA immunoglobulin M (IgM), non–specific protein 1 (NS1) or real–time reverse transcriptase
polymerase chain reaction (RT–PCR) positive results were considered primary/new dengue cases.
Table 2. Frequency of clinical symptoms in dengue fever (DF) patients in Barbados (2008–2016).
Symptoms No. of Patients Frequency (%)
Fever 3702 92.7
Headache 2471 61.9
Joint pain 2103 52.7
Eye pain 1655 41.4
Muscle pain 1533 38.4
Gastrointestinal related symptoms * 1163 29.1
Rash 981 24.6
Anorexia 846 21.2
Bleeding 467 11.7
Respiratory symptoms 308 7.7
Thrombocytopenia 256 6.4
Jaundice 179 4.5
Lethargy 89 2.2
Cough 82 2.1
Hepatomegaly 52 1.3
* Gastrointestinal–related symptoms include vomiting, abdominal pain and diarrhoea.
3.2. Epidemiological Patterns of Dengue in Barbados
During 2008–2016, a total of 3994 laboratory confirmed dengue cases were reported in Barbados.
The DF prevalence rate varied by year from 27.4 to 453.4 cases per 100,000 population annually
(Figure 2A). The emergence of a three–year inter–epidemic interval with DF prevalence rate peaks
in 2010, 2013 and 2016 were observed (Figure 2A). Statistical analysis showed significant differences
in annual DF prevalence rates between the year preceding and the epidemic year for 2009 vs. 2010,
Trop. Med. Infect. Dis. 2020, 5, 68 6 of 20
(27.4 (95% CI, 21.2–33.5) and 194.7 (95% CI, 178.3–211.1) cases per 100,000 population, respectively),
2012 vs. 2013, (176.7 (95% CI, 161.0–192.4) and 453.9 (95% CI, 428.8–478.9) cases per 100,000 population,
respectively) and 2015 vs. 2016 (53.3 (95% CI, 44.7–61.9) and 237.2 (95% CI, 219.1–255.3) cases per
100,000 population, respectively) (Figure 2A). Thus, major dengue epidemics occurred in 2010, 2013
and 2016; the 2013 epidemic started in late 2012, peaked in 2013 and spilled over into 2014 (Figure 2A;
data not shown). The highest DF prevalence rate was observed during 2013 and was significantly
higher than all the years in the study period (Figure 2A).
The highest age adjusted DF prevalence rates were observed in patients 10–19 years of age with
404.7 (95% CI, 378.2–431.4), which was significantly higher than all other age groups, and the next
highest was the 20–29 age group 264.3 (95% CI, 243.4–285.4). (Figure 2B).
The mean monthly DF prevalence rates in Barbados differed significantly from the rainy season
(June to November), with 17.6 (95% CI, 16.0–19.3) cases per 100,000 population, to the dry season
(December to May), with 9.5 (95% CI, 7.9–11.1) cases per 100,000 population (Figure 2C). During
the study period, the cumulative DF prevalence rates increased from June, peaking in October, with
257.8 (95% CI, 238.2–275.9) cases per 100,000 population, then decreasing to lower levels in December
(Figure 2C). Consistently low cumulative DF prevalence rates occurred from January to May (Figure 2C).
Figure 2. Cont.
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Figure 2. (A) Number of dengue fever (DF) cases and prevalence rates among patients seeking medical
attention in Barbados, 2008–2016; (B) DF prevalence and age groups among patients seeking medical
attention in Barbados, 2008–2016; (C) monthly cumulative DF, mean DF, mean dry season and mean
wet season prevalence rates among patients seeking medical attention in Barbados, 2008–2016.
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All four DENV serotypes were observed during the study period 2008–2016, with DENV–2 being
the predominant DENV serotype observed in 2010 and 2011, whilst DENV–1 became the predominant
DENV serotype in 2012 and 2013 (Table 1). DENV serotyping was absent for 2008 and 2014–2016
(Table 1). The predominant serotypes during 2010 and 2013 epidemics were DENV–2 and DENV–1,
respectively, and may explain the fewer SD cases observed in 2013 than in 2010 (Table 1). DENV–3
serotype was the most dominant serotype in 2007; therefore, is it not unusual that the DENV epidemics
observed in 2010 and 2013 were caused predominantly by DENV–2 and DENV–1, respectively.
During the 2010 and 2013 dengue epidemics, the geographic distribution of dengue infections in
Barbados was different. No significant difference was observed in crude DF prevalence rates among
different parishes (Figure 3A). No significant difference was observed for the mean crude DF prevalence
rate among males and females: A total of 153.6 (95% CI, 146.3–164.4) vs. 164.7 (95% CI, 158.2–168.5)
cases per 100,000 population; a ratio of 1:1.
A total of 576 primary dengue cases were observed in the period 2008–2016. The highest
primary dengue prevalence rates were observed in 2013, with 104.0 (95% CI, 92.0–116.0) cases per
100,000 population, and 2012, with 34.2 (95% CI, 27.3–41.1) cases per 100,000 population, which were
significantly higher than other years (Figure 3B). Primary DENV infection accounted for 576 confirmed
patients (14.4%), and at least 2382 (59.6%) secondary DENV infections occurred during 2008 to 2016.
Figure 3. Cont.
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Figure 3. (A) Dengue fever (DF) prevalence rates by geographic location among patients seeking
medical attention in Barbados, 2008–2016; (B) primary (IgM positive only) and secondary (IgM and IgG
positive) DF prevalence rates for patients seeking medical attention in Barbados, 2008–2016; (C) number
of hospitalized DF cases and hospitalized DF prevalence rates among patients seeking medical attention
in Barbados, 2008–2016.
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3.3. Severe Dengue in Barbados
DENV infection in 1356 out of 3994 (34.0%) patients resulted in hospitalizations, and the crude
prevalence rates of hospitalized DF patients ranged from 14.2 (95% CI, 8.2–19.8) cases per 100,000
population to 165.2 (95% CI, 150.1–180.3) cases per 100,000 population between 2008 and 2016
(Figure 3C). During 2013, the crude prevalence rate of hospitalized DF patients, with 165.2 (95% CI,
150.1–180.3) cases per 100,000 population, was significantly higher than every year during the study and
was followed by the crude hospitalized dengue prevalence rate in 2010, with 72.4 (95% CI, 62.3–82.4)
cases per 100,000 population (Figure 3C). SD/DHF prevalence rate varied from 0 to 11.9 (95% CI,
7.8–15.9) cases per 100,000 population (Figure 4A). The mean SD/DHF prevalence rate observed during
the study period was 2.5 (95% CI, 1.2–3.8) cases per 100,000 population. A significantly higher SD/DHF
prevalence rate was observed during 2010, 11.9 (95% CI, 7.8–15.9) cases per 100,000 population than
in every other year in the study, even though a higher DENV prevalence rate was observed in 2013
than in 2010 (Figures 2A and 4A). The 2010 dengue epidemic was more severe than 2013 epidemic
as the SD/DHF prevalence rate in 2010, with 11.9 (95% CI, 7.8–15.9) cases per 100,000 population,
was significantly higher than the SD/DHF prevalence rate in 2013, with 1.8 (95% CI, 0.2–3.4) cases per
100,000 population (Figure 4A).
The CFR among SD/DHF cases varied by age and ranged from 0.0017 to 0.0061, and was highest
among the elderly, persons 60 years or older and the young (0.075 per 100 DF cases), even though the
age adjusted prevalence rate was higher in the 11–25 years old age group (Figure 4B). An overall CFR
of (10/3994) 0.4% was observed over the study period.
Median age of SD/DHF patients varied during 2008–2016, with the highest median age observed
in 2010 (Figure 4C). Most SD/DHF cases in 2012 were young (<30 years old), while in 2010 most DHF
cases were older persons (>30 years old; Figure 4C). The age distribution of the DF patients ranged
from one to 100 years (median 29.6 years) and the median age varied over time (Figure 4C). The median
age of SD/DHF cases was 40 years old (interquartile age range of 23–56 years old) and the median age
varied between 2010 to 2013 (Figure 4C). SD cases were observed in 2009–2013 and an overall mean
age of 35.8 years old was observed over the study period (Figure 4C).
Figure 4. Cont.
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Figure 4. (A) Dengue fever (DF), mean DF, severe dengue (SD)/dengue haemorrhagic fever (DHF)
and mean SD/DHF prevalence rates among patients seeking medical attention in Barbados, 2008–2016;
(B) prevalence rates and case fatality risk (CFR) of SD/DHF by age groups among patients seeking
medical attention in Barbados, 2008–2016; (C) DF and SD/DHF age distribution among patients seeking
medical attention in Barbados, 2008–2016. Boxes encompass 25th and 75th percentiles. Black lines
within the boxes represent medians. Error bars represent the minimum and maximum ranges.
3.4. DENV Sequencing in Dengue Patient Sera
Two out of thirty–three (2/33) DENV specific rRT–PCR positive sera samples yielded E gene
sequences using NGS methods (Figure 5). The viral loads on the remaining 31 samples were too low to
permit sequencing using NGS. Two samples were positive in the rRT–PCR, patients DS18 and DS29,
with cycle threshold (Ct) values of, respectively, 28.5 and 30. Both sequences, GenBank accession
numbers MT269038 (from DS18) and MT269039 (from DS29), grouped closer to DENV–1 strains of
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South–East (SE) Asian origin than to DENV–1 strains from Caribbean or South American origin;
however, the small sample size (n = 2) limits the drawing of any meaningful conclusions (Figure 5).
Figure 5. Phylogenetic analysis of dengue virus type 1 (DENV–1), based on complete envelop gene (E).
The tree was constructed using maximum likelihood (ML) method, with 1000 boot strap resampling.
The boot strap values were mention adjacent to the branch. Patient sample DS18 (MT269038) and DS29
(MT269039) were marked with red dots, different serotypes of dengue NCBI reference strains were
marked with cyan dots.
4. Discussion
Epidemiological data are important in vaccine planning and are critical in measuring vaccine
efficacy and disease burden [18]. The mean dengue prevalence rate observed in this study was
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comparable with previous studies in Barbados (163.0 vs. 162.5 cases per 100,000 population) and more
than double the rate of other countries within the Caribbean and Latin America (163.0 vs. 72.1 cases
per 100,000; P < 0.01) [19]. This prevalence rate remains one of the highest in Caribbean along with
Trinidad, Martinique, Guadeloupe, French Guiana and Puerto Rico [19]. However other Caribbean
territories have significantly lower prevalence rates, as low as 140 times lower [19]. These disparities in
DF prevalence rates may be due to differences in the extensiveness of the DENV laboratory diagnostic
testing and laboratory surveillance systems in each English–speaking Caribbean country. The more
extensive the reporting, the more accurate the prevalence rates. Other factors that contribute are
reduced public health awareness, population density, infecting DENV strain, urban planning activities,
topography, water storage practices, change of lifestyle, apathy and heightened medical seeking
behaviour [20–23]. Variation in the number of laboratory tests conducted can also influence this was
well as more tests conducted will results in more cases detected. A cross–sectional serological survey
within the community may be more representative and accurate as it would be a random sampling
of the population without the bias of patients seeking medical attention which can result in higher
prevalence rates.
A period between dengue epidemics is often observed though the periodic length may vary but
usually is 3 to 5 years in length [12,24–26]. A cyclic pattern of dengue epidemics every 3 years has
been observed in Barbados since 2007 including 2007, 2010, 2013 and possibly 2016 as evidenced
by peak prevalence rates in the period of study [9]. It is noted that ZIKV was first detected in
Barbados during 2016 and the introduction of ZIKV likely increased the number of persons with
DF–like symptoms having flavivirus IgM positive serological results. Only ZIKV molecular testing
can conclusively determine the nature of the clinical infection(s). If interepidemic period of 3–5 years
is consistent the next DENV epidemic in Barbados is likely due in 2020 or 2021 and the possibility
of the concurrent occurrence of severe acute respiratory syndrome coronavirus 2 (SARS CoV–2)
pandemic and a DENV epidemic exists. Reports of suspected DENV infections later being confirmed
as SARS–CoV–2 infections and the similarity with clinical symptoms could lead to complication of
SARS–CoV–2 pandemic response [27–30].
Median age is a predictor of the change in force of infection and mean force of infection [18].
Force of infection is defined as the rate at which susceptible individuals acquire an infectious disease
and it is dependent on several factors including disease prevalence, rate of contact of individuals
(communicable diseases) and infectiousness of individuals [18]. As the median age increases, the force
of infection decreases. The age groups most affected by dengue and DHF/SD can differ in different
geographical locations including SE Asia, Europe and the Americas based partly on differences in the
relative force of infection [31–33]. Dengue endemic areas have a higher force of infection due to the
greater exposure risk to DENV infection by vectors and the higher number of new DENV infections.
The high DF prevalence rates observed in patients 10–19 years is consistent with prevalence data
obtained from other DF endemic locations including Laos [34].
Previous studies have illustrated that gentrification, a shift of the age distribution of human
population toward older ages, increases the risk of severe dengue prevalence [35,36]. In endemic
countries, such as Barbados, the greater proportion of DENV infections were secondary occurring in
persons <20 years. Conversely, for non–endemic countries such as mainland USA, the majority of
DENV infections are primary in nature and occur in older persons 21–60 years old [37]. The implication
of a higher proportion of the population with secondary DENV infection is a higher risk of developing
DHF/SD [38]. The lower the median age of secondary DENV infection the higher is the risk of developing
DHF/SD for younger persons since risk of developing SD/DHF increases with secondary infection.
4.1. Seasonal and Environmental Factors
Climatic factors can enhance vector population growth and increase the risk of DENV vectors
biting susceptible humans [39–41]. Dengue transmission is often seasonal and driven by many climatic
factors including temperature, short and long term rainfall and relative humidity influencing mosquito
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vector growth and density [42–45]. The significant difference between DF prevalence rates during
the rainy and dry seasons in Barbados highlights rainfall as a key factor in DENV transmission as it
permits the proliferation of dengue vectors and increased risk of bites by DENV infected vectors as
observed previously [46–49].
Primarily a higher DF prevalence rate is observed in urban areas versus rural areas as the
population density is higher in urban areas resulting in more susceptible human hosts [50] however in
Barbados, no significant difference in DF prevalence was observed among parishes during the study
period. Population density alone does not influence dengue transmission as other factors such as
degree of vegetation cover and availability of water supply could also influence [51–54].
4.2. Dengue and Gender
Sex bias does occur in infectious disease epidemiology including dengue infections [55]. Among
patients tested positive for DENV infection, males were as likely as females to be infected with DENV
during the study period in Barbados. Higher infection prevalence rates were observed in males from
studies in Asia while reports from the Americas showed either females are more often infected or the
proportion is nearly equal [55–59]. In Asia this disparity was linked to more males in the labour force
and working outdoors [60]. Unlike in Singapore where there are more working males than females,
the skilled labour force in Barbados has a similar number of males and females, 30,454 males vs. 29,872
females, (2010 Barbados census data) [60].
4.3. Dengue Disease Severity
In the Americas, the severe forms of dengue are not as common as in Southeast (SE) Asia as
DHF or DSS attack rates are 18–fold greater in SE Asia than in the Americas [61]. In comparison
the mean SD/DHF prevalence rate in Barbados is lower than Indonesia (30–85 cases per 100,000
population) and several other to SE Asian countries [62,63]. Mean SD/DHF prevalence rate in this
study was comparatively higher to previous studies in Barbados, and other Caribbean countries
excluding Trinidad, Turks and Caicos, Suriname, Bermuda, Montserrat and Cayman Islands [19].
One possible explanation is the improvement of DENV surveillance in Barbados. However, there could
be other possibilities such as viral strain differences, public health awareness, basis of surveillance
(i.e., population based), population age structure, and effectiveness of vector control programs. An
example is the use of only rapid test kits with low sensitivity to diagnose dengue. Moreover, only
samples of severe cases that are send to CARPHA for more sensitive diagnostic testing.
Among SD/DHF cases in Barbados, the highest prevalence rates observed in persons 11–25 years
of age is slightly higher than other countries including Brazil, Sri Lanka and Thailand where SD/DHF
is mostly observed in persons aged 15 or younger [64,65]. Younger members of the population are
more susceptible to dengue infection as they lack substantial immunity however, but this immunity
increases with age as observed in the decline in dengue prevalence rates as age increased. Even though
dengue prevalence has increased in Barbados as in other areas [66–68], attenuation of the severity has
occurred, resulting in a shift in the age distribution of DHF toward older age groups [66,69,70].
The CFR in Barbados is relatively lower than dengue CFRs in most dengue endemic countries
except for Singapore during 2004 and Vietnam during 2010 [62,63]. This lower CFR maybe due
to several factors including easier access to health care, effective mosquito control, water storage
practices, host population genetics, vector biology, geophysical factors and other socioeconomic
differences [49,51,64]. Fatal dengue cases did occur during the study period reviewed but these were
likely underestimated as the reliance on passive case reporting and/or review of death certificates can
fail to identify fatal cases due to misdiagnosis [71–76]. No gender bias exists in Barbados for DHF/SD
as in other countries since males (n = 35) were as likely as females (n = 38) to be infected with DENV
and develop DHF or SD during the study period [55].
All 4 DENV serotypes were in circulation during 2010 epidemic and this likely increased the risk
of developing SD/DHF [12,77,78]. The infecting DENV strain influences the severity of dengue disease
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and the infecting strains in 2010 likely differed from those in 2013 [79]. Sequence data from DENVs in
circulation especially during epidemics can provide useful information regarding strain ‘fitness’ and
the ability to cause severe disease thus should be included as part of routine dengue surveillance and
public health plans [80–82].
4.4. Sequencing of DENV Envelope (E) Gene Region
DENV–1 serotype has been present in the Caribbean since 1970s, being first reported in Jamaica
and was reported as the first DENV serotype to enter Brazil from the Caribbean [83,84]. One study
revealed that DENV–1 was first present in Grenada in the Lesser Antilles, then rapidly spread to South
and Central America and then to the Greater Antilles [83,84]. One phylogenetic study of DENV–1
envelope genes revealed the role of East Asian countries as possible sources of dengue epidemics
and the close relatedness of at least one Caribbean DENV–1 virus to East Asian DENV–1 viruses [85].
The E gene sequence of two RT–PCR positive patient sera samples yielded E gene sequences closer in
relation to DENV–1 isolates of Asian origin, Thailand and Singapore than those from the Caribbean
and South America. Sequencing of DENVs from 2010 outbreak would have been of great interest to
observe their genetic relationship with other sequenced DENVs. However, no deeper insights into
DENVs strain can be since the sample number of sequenced strains (n = 2) is too small. More sequence
data from different time points would be important to perform a thorough analysis.
4.5. Study Limitations
Our study has several limitations including selection bias due to the selection and testing of patients
based on clinical suspicion and is biased due to surveillance, incomplete referral and dengue diagnostic
testing, the potential to miss mild cases and non–symptomatic dengue cases and persistence of
DENV–specific IgM [86]. There are however several strengths of this study due to the key observations
obtained including (a) first sequencing of DENVs from Barbados which bear closer relation to Asian
strains than Caribbean or South American ones, (b) a DENV epidemic periodicity of 3–5 years and the
possible complications for public health officials with current coronavirus disease 2019 (COVID–19)
pandemic planning, (c) lack of gender bias of DENV infection and d) generally a low DENV CFR.
4.6. Future Research
Future research efforts should include analysis of sociodemographic and socioeconomic
determinants of DENV infection, DENV and arboviral research in mosquito vectors to identify
DENV strains in circulation, DENV, ZIKV and CHIKV diagnostic testing of donated blood for
blood banking, DENV seroprevalence studies for any future DENV vaccination efforts and genetic
characterisation of DENV strains to assess the evolution of DENV in Barbados.
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